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Schizophrenia is a chronic, severe, and disabling brain disorder characterized 
by a profound disruption of perception, cognition, and emotion. The condition 
affects approximately 1% of the population and is thought to be the result of 
genetic vulnerability and environmental influences. The symptoms of 
schizophrenia fall into three main categories, i.e. positive symptoms 
(hallucinations, delusions), negative symptoms (apathy, lack of emotion) and 
cognitive symptoms (problems with attention, certain types of memory, and 
executive functions). Antipsychotic medications available effectively alleviate 
the positive symptoms of schizophrenia. However, negative symptoms and 
cognitive deficits remain poorly treated and are considered to belong to a core 
syndrome in schizophrenia. For this reason, investigators are developing more 
effective medications and using new research tools to understand the causes of 
schizophrenia and to find better ways to prevent and treat it. 
 The present issue provides a state of the art review of some of these new 
pharmacological approaches in this rapidly expanding area. Mailman and Murthy 
provide an historical overview of antipsychotic medication and describe functional 
selectivity at D2 dopamine receptors as a novel mechanism of antipsychotic drug action 
[1]. The new concept of functional selectivity posits that a ligand may inherently 
produce a mix of effects through a single receptor depending on the effector pathway 
coupled to that receptor [2]. Thus, it is conceivable that a ligand or drug might target 
not the receptor alone, but a receptor-directed signaling complex. With regard to 
antipsychotic drug action, it was envisaged that if dopamine D2 autoreceptors could be 
preferentially activated with a dopamine agonist, then dopaminergic transmission might 
be diminished, which could lead to a functional dopamine antagonist-like effect. In 
theory, therefore, a low dose of a full agonist could be used to decrease dopamine 
release, thereby causing benefit in schizophrenia. López-Gil and co-workers have 
studied the cortical glutamatergic and serotonergic transmission in an animal model of 
schizophrenia based on NMDA hypofunction [3]. The results suggest that serotonergic 
transmission in the prefrontal cortex is regulated by the concurrent participation of 
multiple monoamine receptors, whereas glutamatergic transmission is strongly 
dependent on dopamine D2-like receptor activation. Thus, although further testing of 
newer antipsychotics is warranted, it seems that so-called atypical antipsychotic drugs 
are able to block increases in cortical glutamate and serotonin elicited by a NMDA 
receptor antagonist. However, classical antipsychotics appear to block only the 
increased glutamatergic transmission. Based on a large study with selective agonist 
and antagonist compounds for which antipsychotic drugs possess some affinity, these 
authors propose that dopamine D2 receptor antagonists would increase cortical 
GABAergic inhibition whereas other monoaminergic compounds (5-HT2A and α1-
adrenergic antagonists as well as 5-HT1A agonist) would be helpful in reducing an 
excessive excitatory transmission in the prefrontal cortex. McCreary and Jones report 
on the beneficial effects of serotonin 5-HT1A receptor agonists in the alleviation of 
symptoms of schizophrenia [4]. There is growing interest in 5-HT1A receptors as 
potential targets for antipsychotic drug action [5]. Indeed, a series of studies using the 
5-HT1A partial agonists tandospirone and buspirone have reported a modest ability of 
these agents to improve some domains of cognition in patients receiving typical or 
atypical antipsychotic drugs. However, it remains to be determined whether these 
compounds act on presynaptic or postsynaptic 5-HT1A receptors. Postsynaptic 5-HT1A 
receptors are highly expressed in the hippocampus, frontal cortex, entorhinal cortex 
and the amygdala, all of which have been implicated in various features of 
schizophrenia. Preclinical studies have evidenced that 5-HT1A receptors located in the 
prefrontal cortex seem to be crucial for the ability of atypical (but not classical) 
antipsychotics to increase cortical dopamine release, an effect potentially involved in 
the improvement of negative symptoms and cognitive dysfunction in schizophrenia. 
Tsai and co-workers [6] have dealt with the importance of increasing NMDA receptor 
mediated glutamatergic transmission in the treatment of schizophrenia [7]. This therapy 
is directly based upon the hypothesis that the illness is caused by an impaired 
glutamatergic transmission at NMDA receptors. These authors report a meta-analysis 
of the efficacy and side effects, in schizophrenia treatment, of agents that enhance 
NMDA receptor neurotransmission via their action at the NMDA receptor-associated 
glycine (Gly) site. Overall, although NMDA-enhancing agents as a group show promise 
in improving some of the symptoms of schizophrenia when added to stable 
antipsychotic treatment, they do not seem to be an option as a sole pharmacological 
treatment of the illness. Finally, Hajós and Rogers provide a timely review of α7 
nicotinic acetylcholine receptors [8], which is an important area of potential therapeutics 
in schizophrenia because α7 nicotinic partial agonists have been shown to exhibit pro-
cognitive and antipsychotic actions [9]. The high level of expression of this receptor 
within the limbic circuitry, including hippocampus and prefrontal cortex is in line with 
their purported involvement in cognitive functions. The stimulation of α7 nicotinic 
acetylcholine receptors by agonists or positive allosteric modulators is believed to 
activate impaired GABA transmission, thus leading to a restitution of gamma-frequency 
oscillations. However, a considerable advance in this field has been done in the 
preclinical setting and there are only very limited data on the cognitive effects of such 
compounds in humans. 
 Overall the contributions of this special issue provide a valuable opportunity for 
a multidisciplinary discussion of approaches to increase our knowledge of the complex 
pharmacology of antipsychotic medications. 
 All the papers in this issue have been subjected to a peer review process. 
Thanks are given to the Editorial Board and referees who have helped to produce this 
issue. 
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